Insight Molecular Diagnostics Yönetim
Yönetim kriter kontrolleri 2/4
Insight Molecular Diagnostics CEO'su Josh Riggs, Dec2022 tarihinde atandı, in görev süresi 3.42 yıldır. in toplam yıllık tazminatı $ 2.59M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.2% maaş ve 81.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler $ 213.31K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 5.3 yıldır.
Anahtar bilgiler
Josh Riggs
İcra Kurulu Başkanı
US$2.6m
Toplam tazminat
| CEO maaş yüzdesi | 18.20% |
| CEO görev süresi | 3.4yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 3yrs |
| Yönetim Kurulu ortalama görev süresi | 5.3yrs |
Son yönetim güncellemeleri
Recent updates
Analiz Makalesi • May 15
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Anlatı Güncellemesi • May 15
IMDX: FDA Submission And Strengthened Cash Position Will Drive Bullish Repricing
Insight Molecular Diagnostics' analyst price target has moved from $8 to $12, with analysts pointing to secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key factors supporting this revision. Analyst Commentary Bullish Takeaways Bullish analysts view the move to a US$12 price target as reflecting reduced funding risk after the recent US$26M offering, which they see as supportive for execution on pending milestones.Anlatı Güncellemesi • Apr 28
IMDX: Upcoming FDA Review And Cash Cushion May Support Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recently completed $26M offering, which secures cash beyond a potential GraftAssureDx approval and an expected FDA submission in the coming weeks, as key drivers of their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the new $12 price target as reflecting improved funding visibility, with the recent $26M offering seen as supportive of ongoing operations past a potential GraftAssureDx approval.Anlatı Güncellemesi • Apr 13
IMDX: Upcoming FDA Submission And Cash Runway May Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26M capital raise and expectations around an upcoming FDA submission for GraftAssureDx as key supports for the new outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a US$12 price target as reflecting higher confidence that the recent US$26M capital raise supports the company through key regulatory milestones.Anlatı Güncellemesi • Mar 29
IMDX: Upcoming FDA Review And Capital Raise Will Support Bullish Repricing
Analysts have raised their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26,000,000 capital raise and the expected FDA submission for GraftAssureDx in the coming weeks as key factors supporting the revised target. Analyst Commentary Recent research updates give you a clearer picture of how the Street is reacting to Insight Molecular Diagnostics after its latest funding and upcoming regulatory milestones.Anlatı Güncellemesi • Mar 12
IMDX: Upcoming FDA Submission And Capital Raise Will Drive Bullish Repricing
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing the recent $26m capital raise and expectations for an upcoming FDA submission for GraftAssureDx as key supports for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the move in the price target to $12 as reflecting higher confidence that the recent $26m capital raise supports the company through key regulatory milestones.Anlatı Güncellemesi • Feb 26
IMDX: Funding And Upcoming FDA Submission Will Shape Potential Upside
Analysts have lifted their price target on Insight Molecular Diagnostics to $12 from $8, citing secured funding from the recent $26M offering and the anticipated FDA submission for GraftAssureDx as key supports for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a $12 price target as reflecting higher conviction that the current funding and product plan can support the company through key milestones.Anlatı Güncellemesi • Feb 11
IMDX: Stable Outlook As Regulatory And Transplant Center Expansion Will Shape Upside
Analysts have adjusted their price target on Insight Molecular Diagnostics to reflect an updated fair value of $7.00 per share, a higher assumed future P/E of 121.71, and revised views on the discount rate and profit margin potential. What's in the News Year-end business update outlined commercial progress and the clinical trial status of the GraftAssureDx test kit, including preparation for an in vitro diagnostic de novo submission to the US Food & Drug Administration (FDA).Anlatı Güncellemesi • Jan 27
IMDX: Stable Outlook As Regulatory Progress And Transplant Testing Portfolio Will Shape Upside
Analysts have nudged their price target on Insight Molecular Diagnostics higher to reflect slightly refined assumptions on discount rate, profit margin and forward P/E. The updated target is now framed around a fair value of 7.0. What's in the News Year end business update outlines commercial progress for the GraftAssureDx test kit, including clinical trial status and plans for an in vitro diagnostic de novo submission to the United States Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026 (company update).Anlatı Güncellemesi • Jan 12
IMDX: Stable Outlook As Transplant Monitoring Pipeline And Regulatory Progress Will Support Upside
Narrative Update on Insight Molecular Diagnostics Analysts have slightly adjusted their price target on Insight Molecular Diagnostics, with the change reflecting updated fair value modeling around a 7.0% discount rate, approximately 41% revenue growth assumptions, a 16.24% profit margin, and a forward P/E near 120x. What's in the News Year end business update provided on commercial progress, including the GraftAssureDx test kit clinical trial and plans for an in vitro diagnostic de novo submission to the US Food & Drug Administration, alongside additional regulatory submissions and registry study work expected in 2026.Anlatı Güncellemesi • Dec 25
IMDX: Transplant Monitoring Expansion Will Drive Future Market Leadership
Analysts have modestly raised their price target on Insight Molecular Diagnostics to reflect incremental improvements in long term profit margin assumptions and a slightly lower discount rate, while maintaining broadly consistent growth expectations and valuation multiples. What's in the News Publication of a case study in the American Journal of Transplantation highlighted Insight Molecular Diagnostics' GraftAssure assay as essential for monitoring a high risk kidney transplant patient undergoing novel CD19 CAR T therapy without traditional immunosuppression (Key Developments).Anlatı Güncellemesi • Dec 11
IMDX: Transplant Monitoring Advances Will Drive Future Market Momentum
Narrative Update on Insight Molecular Diagnostics The analyst price target for Insight Molecular Diagnostics has been modestly revised upward by analysts, reflecting slightly higher fair value estimates supported by incremental improvements in projected discount rate, revenue growth, profit margin, and future price to earnings assumptions. What's in the News A published clinical study in the American Journal of Transplantation highlighted the GraftAssure assay as critical for long-term monitoring of a high-risk kidney transplant patient treated with novel CD19 CAR T therapy, confirming absence of rejection during cancer treatment (American Journal of Transplantation).Anlatı Güncellemesi • Nov 27
IMDX: Expanding Clinical Trial Participation Will Drive Market Momentum
Analysts have raised their price target for Insight Molecular Diagnostics from $6.13 to $7.00 per share, citing stronger expected revenue growth and improving profit margins in their updated forecasts. What's in the News Insight Molecular Diagnostics published results showing their GraftAssure assay enabled long-term non-immunosuppressed kidney transplant survival with no rejection, following CD19 CAR-T therapy in a complex patient case (study published in the American Journal of Transplantation).Seeking Alpha • Nov 14
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating
Summary Initiating coverage of Insight Molecular Diagnostics Inc. with a Hold rating due to upcoming catalysts and pending FDA submission for GraftAssureDx kidney transplant assay. IMDX's decentralized GraftAssureDx aims to disrupt the $1B+ transplant rejection testing market, offering cost-effective, localized testing versus centralized lab competitors. Key risks include clinical validation, regulatory approval uncertainty, software readiness, potential FDA delays, and a limited cash runway likely requiring further capital raises. Applying a Hold rating as IMDX advances toward FDA filing by end-2025 and eyes expansion into heart and lung transplant assays in 2026 and 2027. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 12
We Think Insight Molecular Diagnostics (NASDAQ:IMDX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, Insight...Anlatı Güncellemesi • Nov 12
IMDX: Increased Discount Rate Will Raise Uncertainty for Share Performance
Analysts have raised their price target for Insight Molecular Diagnostics from $5.42 to $6.13, citing improved revenue growth forecasts and higher profit margins as key factors contributing to the increased valuation. What's in the News Insight Molecular Diagnostics published study results in the American Journal of Transplantation, demonstrating the value of its GraftAssure assay for monitoring kidney transplant patients with severe complications.
Yeni Anlatı • Apr 13
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$48m |
| Dec 31 2025 | US$3m | US$472k | -US$50m |
| Sep 30 2025 | n/a | n/a | -US$61m |
| Jun 30 2025 | n/a | n/a | -US$63m |
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$786k | US$385k | -US$61m |
| Sep 30 2024 | n/a | n/a | -US$44m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$725k | US$340k | -US$26m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$514k | US$242k | -US$19m |
Tazminat ve Piyasa: Josh 'nin toplam tazminatı ($USD 2.59M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.74M ).
Tazminat ve Kazançlar: Josh şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Josh Riggs (42 yo)
3.4yrs
Görev süresi
US$2,594,786
Tazminat
Mr. Joshua Riggs, also known as Josh, serves as Director of Insight Molecular Diagnostics Inc. (formerly known as OncoCyte Corporation) since February 28, 2023, serves as its Chief Executive Officer & Pres...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 3.4yrs | US$2.59m | 0.12% $ 213.3k | |
| Chief Financial Officer | 1.9yrs | US$1.68m | 0.64% $ 1.1m | |
| VP of Accounting | 3.7yrs | US$454.99k | 0% $ 0 | |
| Chief Technology Officer | 3yrs | Veri yok | Veri yok | |
| Chief Science Officer | 3.3yrs | US$633.57k | 0.064% $ 114.8k | |
| VP, General Counsel & Secretary | 2.3yrs | Veri yok | Veri yok | |
| Vice President of Marketing | no data | Veri yok | Veri yok | |
| Senior Vice President of Business Operations | 2.8yrs | Veri yok | Veri yok | |
| Consulting Chief Medical Officer | 1.3yrs | Veri yok | Veri yok | |
| Scientific Advisor | 10.6yrs | US$328.84k | Veri yok | |
| Sr. Executive Assistant | no data | Veri yok | Veri yok |
3.0yrs
Ortalama Görev Süresi
43yo
Ortalama Yaş
Deneyimli Yönetim: IMDX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 3.3yrs | US$2.59m | 0.12% $ 213.3k | |
| Independent Director | 3.5yrs | US$191.83k | 0.0048% $ 8.7k | |
| Independent Chairman | 10.9yrs | US$312.63k | 0.30% $ 540.2k | |
| Member of Scientific & Medical Advisory Board | 5.3yrs | Veri yok | Veri yok | |
| Member of Scientific & Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific & Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific & Medical Advisory Board | 5.3yrs | Veri yok | Veri yok | |
| Independent Director | 10.4yrs | US$191.83k | 0.014% $ 25.1k | |
| Member of Scientific & Medical Advisory Board | 5.3yrs | Veri yok | Veri yok | |
| Member of Scientific & Medical Advisory Board | 5.3yrs | Veri yok | Veri yok | |
| Member of Scientific & Medical Advisory Board | 5.3yrs | Veri yok | Veri yok |
5.3yrs
Ortalama Görev Süresi
65.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: IMDX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/20 04:58 |
| Gün Sonu Hisse Fiyatı | 2026/05/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Insight Molecular Diagnostics Inc. 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| null null | KeyBanc Capital Markets Inc. |